NCT00556088

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

A Phase I Study of LBH589 in Combination With Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I protocol will evaluate the safety and tolerability of the combination of LBH589 and paclitaxel/carboplatin. The combination of LBH589, paclitaxel/carboplatin, and bevacizumab will also be evaluated for tolerability and preliminary antitumor activity in a subset of patients with advanced non-small cell lung cancer.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	LBH589, Paclitaxel, Carboplatin, Bevacizumab	LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days. Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer.

Timeline

• Start date: 2007-12-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2007-11-09
• Last updated: 2010-12-30

Locations

1 site across 1 country: United States